Journal of Personalized Medicine | |
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance | |
Wen-Shuo Wu1  | |
[1] Department of Chest Medicine, Taipei Veteran General Hospital, Yang-Min National University, No. 21, Sec. 2, Shi-Pai Rd., Taipei 11217, Taiwan; E-Mail | |
关键词: epidermal growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI); non-small cell lung cancer (NSCLC); | |
DOI : 10.3390/jpm4030297 | |
来源: mdpi | |
【 摘 要 】
In the era of personalized medicine, epidermal growth factor receptor (EGFR) inhibition with tyrosine kinase inhibitor (TKI) has been a mainstay of treatment for non-small cell lung cancer (NSCLC) patients with an
【 授权许可】
CC BY
© 2014 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190024276ZK.pdf | 464KB | download |